191 related articles for article (PubMed ID: 32795085)
1. Continuing Burden of Refractory Epilepsy.
Janson MT; Bainbridge JL
Ann Pharmacother; 2021 Mar; 55(3):406-408. PubMed ID: 32795085
[TBL] [Abstract][Full Text] [Related]
2. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Wheless JW
Expert Rev Neurother; 2020 Nov; 20(11):1085-1098. PubMed ID: 33031714
[TBL] [Abstract][Full Text] [Related]
4. The burden of epilepsy and unmet need in people with focal seizures.
Ioannou P; Foster DL; Sander JW; Dupont S; Gil-Nagel A; Drogon O'Flaherty E; Alvarez-Baron E; Medjedovic J
Brain Behav; 2022 Sep; 12(9):e2589. PubMed ID: 36017757
[TBL] [Abstract][Full Text] [Related]
5. Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy.
Buckley CT; Waters OR; DeMaagd G
Ann Pharmacother; 2021 Mar; 55(3):318-329. PubMed ID: 32623899
[TBL] [Abstract][Full Text] [Related]
6. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy.
Lancman ME; Fertig EJ; Trobliger RW; Perrine K; Myers L; Iyengar SS; Malik M
Epilepsy Behav; 2016 Aug; 61():27-33. PubMed ID: 27315132
[TBL] [Abstract][Full Text] [Related]
7. The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?
Ben-Menachem E; Schmitz B; Kälviäinen R; Thomas RH; Klein P
Epilepsy Behav; 2023 Nov; 148():109435. PubMed ID: 37748414
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy.
Bohosova J; Vajcner J; Jabandziev P; Oslejskova H; Slaby O; Aulicka S
Epilepsia; 2021 Nov; 62(11):2573-2588. PubMed ID: 34486106
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
10. Quantifying the burden of generalized tonic-clonic seizures in patients with drug-resistant epilepsy.
Sheikh SR; Thompson N; Frech F; Malhotra M; Jehi L
Epilepsia; 2020 Aug; 61(8):1627-1637. PubMed ID: 32658343
[TBL] [Abstract][Full Text] [Related]
11. The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.
Wilcox KS; West PJ; Metcalf CS
Neuropharmacology; 2020 Apr; 166():107811. PubMed ID: 31790717
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy.
Catalán-Aguilar J; Hampel KG; Cano-López I; Garcés M; Lozano-García A; Tormos-Pons P; González-Bono E; Villanueva V
Epilepsia Open; 2024 Feb; 9(1):223-235. PubMed ID: 37920923
[TBL] [Abstract][Full Text] [Related]
13. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
[TBL] [Abstract][Full Text] [Related]
14. The current and emerging therapeutic approaches in drug-resistant epilepsy management.
Mehdizadeh A; Barzegar M; Negargar S; Yahyavi A; Raeisi S
Acta Neurol Belg; 2019 Jun; 119(2):155-162. PubMed ID: 30868468
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.
Chi X; Huang C; Li R; Wang W; Wu M; Li J; Zhou D
J Mol Neurosci; 2017 Apr; 61(4):553-562. PubMed ID: 28229367
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the action mechanisms and targets of herbal anticonvulsants highlights opportunities for therapeutic engagement with refractory epilepsy.
Tabassum S; Shorter S; Ovsepian SV
J Mol Med (Berl); 2024 Jun; 102(6):761-771. PubMed ID: 38653825
[TBL] [Abstract][Full Text] [Related]
17. Developing a gene panel for pharmacoresistant epilepsy: a review of epilepsy pharmacogenetics.
Rodriguez-Acevedo AJ; Gordon LG; Waddell N; Hollway G; Vadlamudi L
Pharmacogenomics; 2021 Mar; 22(4):225-234. PubMed ID: 33666520
[TBL] [Abstract][Full Text] [Related]
18. Changing characteristics of epilepsy interventional clinical trials over the last decade: Clinicaltrials.Gov registry.
Eslami V; Lola MC; Karceski SC; Cavazos JE; Szabó CÁ
Epilepsy Res; 2020 Aug; 164():106350. PubMed ID: 32447238
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia.
Neubauer D; Perković Benedik M; Osredkar D
Epilepsy Behav; 2018 Apr; 81():79-85. PubMed ID: 29526578
[TBL] [Abstract][Full Text] [Related]
20. Dietary effects on antiseizure drug metabolism and management of epilepsy.
Tayutivutikul N; Wanleenuwat P; Panapongvasin T; Klajing R; Iwanowski P
Seizure; 2022 Nov; 102():14-21. PubMed ID: 36156390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
